Ficonalkib

Ficonalkib
Clinical data
Other names	CT-3505; LTK tyrosine kinase inhibitor; SY-3505
Legal status
Legal status	investigational;
Identifiers
	IUPAC name 2-N-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl]-4-N-(2-propan-2-ylsulfonylphenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-2,4-diamine;
CAS Number	2233574-95-1;
PubChem CID	135211735;
IUPHAR/BPS	12378;
DrugBank	DB18774;
ChemSpider	128921345;
UNII	8EPZ3U4PSS;
ChEBI	CHEBI:759167;
ChEMBL	ChEMBL5314461;
Chemical and physical data
Formula	C29H39N7O3S
Molar mass	565.74 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC3=C2CCN3)NC4=C(C=C(C=C4)N5CCC(CC5)N(C)C)OC;
	InChI InChI=InChI=1S/C29H39N7O3S/c1-19(2)40(37,38)26-9-7-6-8-24(26)31-28-22-12-15-30-27(22)33-29(34-28)32-23-11-10-21(18-25(23)39-5)36-16-13-20(14-17-36)35(3)4/h6-11,18-20H,12-17H2,1-5H3,(H3,30,31,32,33,34); Key:LDTJJGGYLQQRSP-UHFFFAOYSA-N;

Ficonalkib is an investigational new drug that is being evaluated by Shouyao Holdings for the treatment of non-small cell lung cancer (NSCLC). It is an anaplastic lymphoma kinase (ALK) inhibitor.^[1]^[2]^[3]

Ficonalkib is a third generation ALK inhibitor that is active against both wild-type as well as a range of resistant mutants that develop from first and second generation ALK targeted drugs.^[4]

Clinical trials

Ficonalkib is currently in phase 3 clinical trials for non-small cell lung cancer.^[5]

References

↑ "Ficonalkib - Shouyao Holdings". AdisInsight. Springer Nature Switzerland AG.
↑ Zhou L, Jiang J (2026). "Non-small cell lung cancer research: advances and persistent challenges". Frontiers in Oncology. 16 1729747. doi:10.3389/fonc.2026.1729747. PMC 13079009. PMID 41994634.
↑ Basmajian K, Stepanyan Z, Sarkissian S (July 2026). "A Systematic Review and Meta-analysis of Clinical Trials in ALK-positive Non-small Cell Lung Cancer". Anticancer Research. 46 (7): 3609–3618. doi:10.21873/anticanres.18227. PMID 42373241.
↑ Britton F, Gomez-Randulfe I, Mrak L, Califano R (January 2024). "Ficonalkib: a new contender in ALK-positive non-small cell lung cancer treatment". AME Clinical Trials Review. 2: 98. doi:10.21037/actr-24-124.
↑ Clinical trial number NCT06254599 for "A Study of SY-3505 Versus Crizotinib In First Line Treatment of Patients with ALK-Positive NSCLC" at ClinicalTrials.gov

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.

[AdisInsight-1] "Ficonalkib - Shouyao Holdings". AdisInsight. Springer Nature Switzerland AG.

[Zhou_2026-2] Zhou L, Jiang J (2026). "Non-small cell lung cancer research: advances and persistent challenges". Frontiers in Oncology. 16 1729747. doi:10.3389/fonc.2026.1729747. PMC 13079009. PMID 41994634.

[Basmajian_2026-3] Basmajian K, Stepanyan Z, Sarkissian S (July 2026). "A Systematic Review and Meta-analysis of Clinical Trials in ALK-positive Non-small Cell Lung Cancer". Anticancer Research. 46 (7): 3609–3618. doi:10.21873/anticanres.18227. PMID 42373241.

[4] Britton F, Gomez-Randulfe I, Mrak L, Califano R (January 2024). "Ficonalkib: a new contender in ALK-positive non-small cell lung cancer treatment". AME Clinical Trials Review. 2: 98. doi:10.21037/actr-24-124.

[5] Clinical trial number NCT06254599 for "A Study of SY-3505 Versus Crizotinib In First Line Treatment of Patients with ALK-Positive NSCLC" at ClinicalTrials.gov

[1]

[2]

[3]

[4]

[5]